ProQR Therapeutics N.V. (PRQR) Shareholder/Analyst Call Transcript

AX-0810 Phase I healthy volunteer trial is ongoing with an upcoming target engagement readout expected; ProQR hosted a virtual investor/analyst event on April 8, 2026. CEO Daniel de Boer will provide a pipeline overview and CMO Cristina Lopez Lopez will discuss AX-0810 indication selection and timing for the initial readout. The call is informational and outlines development plans rather than reporting clinical or financial results.

Analysis

A single near-term binary biomarker event for a small-cap oligonucleotide developer functions as a de-risking lever for the entire modality: a clean positive signal typically shortens partnering timelines and expands acquisition interest, while a negative or ambiguous signal often forces financing and compresses multiples across peers. Expect the readout to act less like incremental data and more like an option exercise — value accrues non-linearly to platform owners that demonstrate reproducible, on-target pharmacology.

Second-order supply effects matter: if the program validates modality-specific delivery/chemistry, demand for specialized GMP oligo manufacturing will jump, tightening slots at CDMOs that already run constrained pipelines; that can create multi-month bottle­necks, widening time-to-market spreads between well-capitalized partners and small developers. Conversely, a negative outcome accelerates investor flight from the sector, amplifying dilution risk as smaller names tap public markets at lower prices.

Key risks are assay sensitivity and endpoint interpretation — modest target engagement can be dismissed as inconclusive rather than a near-term failure, delaying value realization for 6–18 months. Regulatory and commercial timing is measured in years, but market moves will concentrate into days-weeks around announcement windows; liquidity and option markets are likely to gap, so execution and defined-loss structures are critical.

From a positioning standpoint, the cleanest way to express upside is controlled asymmetry: buy defined-risk call spreads or equity with short-dated protective puts; hedge modality exposure via pairs or by owning CDMOs that benefit from validated demand. The market is polarized — it either underprices platform optionality (if positive) or overreacts to single-event ambiguity (if negative), creating tradeable dislocations in both directions.

Key Decisions for Investors

• Directional asymmetric (PRQR): Buy PRQR shares sized to 1–2% portfolio notional and simultaneously buy 30–60 day at-the-money puts for 25–35% notional to cap downside; if the near-term readout is positive expect >2x equity move, downside limited to put cost + equity loss (~10–20%).
• Defined-risk options (PRQR): Buy a 2–3 month call spread (buy near-term ATM call, sell 1.3–1.5x strike) sized to 0.5–1% notional to capture binary upside while funding part of the premium; target >=2:1 upside-to-max-loss if event confirms modality validation.
• Pair trade to isolate modality (Long PRQR / Short IONS): Pair equal notional long PRQR with short Ionis (IONS) to concentrate on event-specific upside while hedging sector beta; hold 1–3 months, unwind on readout, expect >30% relative move if event is decisive, tail risk is broader biotech selloff.
• Supply-chain hedge/long (CTLT): Buy Catalent (CTLT) with a 6–12 month horizon to capture potential increase in oligo CDMO demand if modality is validated; treat as a quality cyclical with expected mid-teens relative upside vs small-cap biotech conditional on cadence of partnering deals.